戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 diameter, volumetric coronary blood flow, or coronary vascular resistance.
2   CAB-2 also retarded the onset of increased coronary vascular resistance.
3 brillation and the accompanying increases in coronary vascular resistance.
4 t percent changes in coronary blood flow and coronary vascular resistance (-31 +/- 4% versus -7 +/- 3
5                               A reduction in coronary vascular resistance and a decrease in coronary
6 ects on energy metabolism without effects on coronary vascular resistance and coronary blood flow.
7 fic antagonist of nitric oxide synthesis, on coronary vascular resistance and epicardial coronary art
8 MA, the 13 +/- 4% (mean +/- SEM) increase in coronary vascular resistance and the 4 +/- 1% lumen diam
9 h a higher coronary effluent PCO2, increased coronary vascular resistance, and development of ischemi
10 elopment of ischemic contracture, increasing coronary vascular resistance, and favoring the developme
11  length area, coronary artery blood flow and coronary vascular resistance, and myocardial oxygen cons
12  [*p < 0.05 vs. baseline value]) and reduced coronary vascular resistance (baseline, 1.6 +/- 0.3 mm H
13 -8%, P<.05, respectively) and an increase in coronary vascular resistance (CVR) (242+/-18% versus 110
14 (13)N]ammonia PET imaging to measure MBF and coronary vascular resistance (CVR) at rest and during a
15 and Doppler flow velocity were measured, and coronary vascular resistance (CVR) was calculated during
16                                              Coronary vascular resistance (CVR; mean arterial pressur
17 mulation was performed, measuring changes in coronary vascular resistance (% delta CVR) before and af
18                    We measured the change in coronary vascular resistance (DeltaCVR) and epicardial d
19                                    Change in coronary vascular resistance (DeltaCVR) was measured as
20 Hg/s; P < .01) and coronary vasoconstrictor (coronary vascular resistance: first dose, +38 +/- 9% fro
21  decreased coronary blood flow and increased coronary vascular resistance in normal dogs; this effect
22 unction, determined as the percent change in coronary vascular resistance in response to ACH (P=0.009
23 e percent changes in coronary blood flow and coronary vascular resistance in the TIVCC compared with
24                                            A coronary vascular resistance index (CVR) was calculated
25          Cardiac pacing-induced reduction in coronary vascular resistance of 27+/-4% (p < 0.001) rema
26 ompromised by other mechanisms that increase coronary vascular resistance or reduce coronary driving
27 o significant effect on coronary blood flow, coronary vascular resistance, or coronary artery diamete
28 5) as the result of a 44 +/- 13% increase in coronary vascular resistance (p < 0.05).
29  (+15 +/- 4 from 41 +/- 4 ml/min), while the coronary vascular resistance response was greater in bab
30 stemic pressor, inotropic, chronotropic, and coronary vascular resistance responses to cocaine (1 mg/
31 ry artery diameter, coronary blood flow, and coronary vascular resistance were calculated on the basi
32 sclerotic patients (32.2 +/- 9% reduction in coronary vascular resistance with 10(-6) mol/liter acety

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。